A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

<p>Abstract</p> <p>Background</p> <p>The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Roy Andre, Rostaing Lionel, Rossi Giorgio, Rizell Magnus, Pirenne Jacques, Pinna Antonio D, Pageaux Georges-Philippe, Otto Gerd, Mutzbauer Ingrid, Mazzaferro Vincenzo, Margreiter Raimund, Mäkisalo Heikki, Lerut Jan P, Lamby Philipp E, Königsrainer Alfred, Jamieson Neville, Hidalgo Ernest, Heise Michael, Hauss Johann P, Gugenheim Jean, Fändrich Fred, Colledan Michele, Cillo Umberto, Chazouillères Olivier, Beckebaum Susanne, Becker Thomas, Bechstein Wolf O, Adam Rene, Kneteman Norman M, Duvoux Christophe, de Jong Koert P, Burra Patrizia, Bilbao Itxarone, Rochon Justine, Graeb Christian, Zuelke Carl, Schnitzbauer Andreas A, Turrion Victor, Schmidt Jan, Troisi Roberto I, van Hoek Bart, Valente Umberto, Wolf Philippe, Wolters Heiner, Mirza Darius F, Scholz Tim, Steininger Rudolf, Soderdahl Gunnar, Strasser Simone I, Jauch Karl-Walter, Neuhaus Peter, Schlitt Hans J, Geissler Edward K
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2010-05-01
coleção:	BMC Cancer
Acesso em linha:	http://www.biomedcentral.com/1471-2407/10/190
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!